Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.51 USD
0.00 (0.00%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACET 1.51 0.00(0.00%)
Will ACET be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACET based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACET
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Why Adicet Bio (ACET) Stock Might be a Great Pick
ACET: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Other News for ACET
Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma